Sean P. Collins, MD, PhD, presented “Radiation Therapy Planning Using Advanced Imaging – Pearls and Pitfalls” during the 8th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8, 2024.
How to cite: Collins, Sean P. “Radiation Therapy Planning Using Advanced Imaging – Pearls and Pitfalls.” October 8, 2024. Accessed Feb 2025. https://grandroundsinurology.com/radiation-therapy-planning-using-advanced-imaging-pearls-and-pitfalls-2/
Radiation Therapy Planning Using Advanced Imaging – Pearls and Pitfalls – Summary
This 7-minute presentation by Sean Collins, MD, PhD, a radiation oncologist at Tampa General Hospital, provides an in-depth exploration of POSLUMA, a new PSMA-specific PET imaging agent approved in May 2023 for prostate cancer.
Dr. Collins presents clinical scenarios demonstrating POSLUMA’s impact on staging and treatment planning. These findings can lead to significant management changes, including adjusted radiation doses, expanded fields, or shifts to systemic therapy for widespread disease.
Dr. Collins highlights challenges, such as renal excretion, and potential solutions and treatment. Importantly, POSLUMA exhibits lower bladder activity than other renal-cleared PSMA agents, potentially reducing risks like misidentification of ureters as lymph nodes.
Dr. Collins underscores the agent’s utility in refining treatment plans, especially for high-risk and recurrent prostate cancer.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Sean P. Collins, MD, PhD, is a clinical associate professor at Georgetown University Hospital in Washington, DC. He joined his twin brother Brian on the faculty of the cancer center in July of 2006 as an attending physician in radiation oncology. Dr. Collins graduated from the Medical Scientist Training Program (MSTP) at the University of Michigan in 2001. Professor Collins completed both an internship in surgery and a residency in radiation oncology at Georgetown University Hospital. His area of expertise is prostate cancer, for which he treats patients using the CyberKnife®, a technology that allows for more accurate targeting of radiation therapy. Dr. Collins is a physician-scientist, and his work focuses on developing prostate cancer treatment protocols using stereotactic body radiation therapy (SBRT) to minimize the toxicity of radiation dose escalation. To date, he has treated over 2000 prostate cancer patients with SBRT and has presented his work at major meetings and published multiple papers on his experience in peer reviewed journals.
